Minerva Neurosciences Announces President's Departure, Executive Payout, and New CBO/General Counsel Appointment

summarizeSummary

Minerva Neurosciences announced the resignation of its President, Geoffrey Race, effective March 31, 2026, alongside a significant severance package and the appointment of James O'Connor as Chief Business Officer and General Counsel.

check_boxKey Events

• President's Resignation

  Geoffrey Race resigned as President of Minerva Neurosciences and Director of its subsidiary Mind-NRG, effective March 31, 2026, after 16 years with the company.

• Substantial Separation Package

  The company agreed to a settlement including a cash payout of approximately $676,000, covering annual salary, pension, medical, life assurance, pro-rated bonus, severance, and legal fees.

• Accelerated Equity Vesting

  All of Mr. Race's outstanding stock options were fully vested as of March 31, 2026, with an extended exercise period until January 1, 2030.

• Consultancy Agreement

  Mr. Race will continue to provide consulting services for one year at £333 per hour (minimum 35 hours/month) and may be eligible for additional stock options.

auto_awesomeAnalysis

This filing details a significant leadership transition at Minerva Neurosciences, with the departure of long-serving President Geoffrey Race. The company will incur substantial separation costs, including a cash payout of approximately $676,000 and the immediate vesting of all of Mr. Race's outstanding stock options, which could lead to future dilution. This executive change occurs against a backdrop of the company's challenging financial position, including a massive net loss in 2025 and ongoing drug development delays. The appointment of James O'Connor as Chief Business Officer and General Counsel, along with Mr. Race's continued involvement as a consultant, aims to provide continuity and new leadership, but the overall impact is mixed given the financial implications and the company's current state.